Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.41 |
| ▸ | LPL | P06858 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17439342 | 0.82 | LIPG (0.51) | LTA4HLIPGLPLHTTMAOB | |
| SCHEMBL3260125 | 0.80 | LIPG (0.56) | LIPGLPLDGAT1HTTALDH1A1 | |
| SCHEMBL17800073 | 0.78 | DGAT1 (0.49) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL10269020 | 0.77 | LPL (0.56) | LIPGLPLHTT | |
| SCHEMBL3461798 | 0.77 | SMN1; SMN2 (0.57) | RAB9AHTTALDH1A1 | |
| SCHEMBL29789810 | 0.77 | POLB (0.51) | DGAT1RAB9APDGFRBKDRHTT | |
| SCHEMBL28822828 | 0.77 | POLB (0.51) | DGAT1RAB9APDGFRBKDRHTT | |
| SCHEMBL15550766 | 0.76 | DGAT1 (0.53) | LIPGLPLDGAT1PDGFRBPDGFRA | |
| SCHEMBL31240616 | 0.76 | DGAT1 (0.53) | LIPGLPLDGAT1PDGFRBPDGFRA | |
| SCHEMBL24137532 | 0.75 | HTR7 (0.49) | LIPGLPLPDGFRBKDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
| WO-2021263129-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-2858990-B1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | ABBVIE INC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9561231-B2 | Pyridinone and pyridazinone derivatives | ABBVIE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2858990-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | AbbVie Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-2858982-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | AbbVie Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013185284-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | ABBOTT LABORATORIES (US) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013188381-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | ABBVIE INC. (US) | 2013-12-19 | — | — | WO | disclosed |
| US-20130331382-A1 | Pyridinone and Pyridazinone Derivatives | ABBVIE INC. | 2013-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | LTA4H 2949/4885KCNH2 718/4885LIPG 783/4885 |
| US-20130331382-A1 | Pyridinone and Pyridazinone Derivatives | CYP4F3, CYP4B1, CYP4F11 | LTA4H 503/4885KCNH2 1763/4885LIPG 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.